BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Novo Nordisk Canada Inc. (NVO) Release: Is there Sexual Intimacy After Menopause? Canadian Women Reveal Greater Need for Physician-Women Dialogue Regarding Vaginal Health


6/26/2012 1:22:34 PM

~ 82 per cent of Canadian women agree that vaginal atrophy would have a negative impact on their life, including sexual intimacy, yet only seven per cent are aware of the condition ~

TORONTO, June 26, 2012 /CNW/ - According to new data from the VIVA (Vaginal Health: Insights, Views & Attitudes) survey presented at the Society of Obstetricians and Gynaecologists of Canada (SOGC) Annual Clinical Meeting, seventy-two per cent of Canadian women consider sexual intimacy as being the area of their life most likely to be affected by the symptoms of a chronic condition of menopause called vaginal atrophy or VA.1 Although approximately half of postmenopausal Canadian women experience symptoms of VA,2 the VIVA survey shows that many shy away from initiating discussions around vaginal health with their doctor, and often doctors are not proactively discussing it.3

Vaginal atrophy is a common, treatable condition where the vaginal walls become thin, fragile and inflamed due to a reduction of estrogen.4 Symptoms include: burning, itching, dryness, irritation and painful intercourse.5 These symptoms get worse over time - and yet no one is talking.

"Knowledge of vaginal atrophy is low in Canada and the symptoms can affect a woman's overall health, sexual intimacy, relationships and self-confidence," said Dr. Rossella Nappi, co-author of the VIVA Survey and Associate Professor of Obstetrics and Gynaecology at the University of Pavia in Italy. "We are calling on healthcare professionals to routinely raise the topic of vaginal health with their postmenopausal patients and to discuss appropriate treatment options to improve quality of life."

In fact, guidelines from the SOGC, a leading authority on women's health issues, state that doctors should routinely assess their patients for signs and symptoms of VA and discuss available treatment options.6

A Chronic Condition Kept Under the Covers

According to the VIVA findings few women are seeking medical assistance, and many are hesitant to talk to their doctor about vaginal health, either due to embarrassment, cultural values, or acceptance of such symptoms as an inevitable consequence of aging. One-third (32 per cent) of Canadian respondents who have suffered from VA waited more than a year before seeing a healthcare professional1A and over half (56 per cent) experienced symptoms for three years or longer.1B

"Vaginal atrophy is very common and can affect a woman's quality of life, but unfortunately the VIVA results show women expressed that their healthcare provider had not raised the subject with them," said Dr. Sheldon M. Frank, MD, medical director, Temple Green Clinic for menopausal women, Kitchener, Ontario, and certified NAMS practitioner. "Canadian healthcare providers have a key role to play in sparking the discussion, just as much as women. These discussions are imperative to help women understand VA so they can find a treatment option, such as low dose local estrogen therapy, to help their condition, rather than live with the symptoms and suffer in silence."

Joan Boone's Story - No More Suffering in Silence

Joan Boone, a Canadian Boomer who started experiencing vaginal symptoms at an early age, is one of many women who was embarrassed to speak to a doctor. Joan has boldly emerged from the shadows to shed light on VA, a condition which had once prevented her from enjoying life.

"For a long time I experienced symptoms of VA which made me very uncomfortable and prevented me from doing the things I love like swimming and cycling," said Joan. "Symptoms affected my relationships, especially with my husband, and my life was coming to a halt. I finally spoke to my doctor and that's the best decision I could have made. After receiving treatment, I felt renewed. I was in a better mood, my relationship with my husband was healthier and it improved my overall quality of life."

VA - The "Hush-Hush" Condition of Menopause According to VIVA Results:

The international VIVA (Vaginal Health: Insights, Views & Attitudes) survey was commissioned by Novo Nordisk and conducted by Strategy One and obtained information from 3,520 female respondents aged 55-65 years old from Great Britain, Sweden, Denmark, Finland, Norway, the United States of America and included 500 Canadians. The survey assessed their understanding of VA and its overall impact. Key Canadian findings include:

  • Only seven per cent could accurately name VA as the condition that included symptoms of vaginal dryness, pain during sex, itching, burning and soreness of the vagina1C
  • Less than half of survey respondents considered that enough information was available about the symptoms and treatment of vaginal discomfort1D
  • Eight in ten(82 per cent) agreed VA would have a negative impact on various aspects of their life1E
  • The majority of women surveyed agree that VA could limit their comfort of doing what they want to do, when they want to do it1F
  • Almost three-quarters of women agree that VA can have negative consequences on a woman's sex life, followed by their ability to have a loving relationship (39 per cent)1G
  • Over half of Canadian women surveyed lack knowledge about local estrogen therapy7
  • Of the Canadian women surveyed, 43 per cent would consider local estrogen therapy, if it would keep their hormone levels normal1H

For more information about vaginal atrophy, visit TheBigOw.ca. It can't hurt!

About Novo Nordisk Canada Inc.

Novo Nordisk is a healthcare company and a world leader in diabetes care and biopharmaceuticals. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. For more information, visit www.novonordisk.ca.

References:

______________________________
1 Novo Nordisk Canada Topline Report: Vaginal Health: Insights, Views and Attitudes. September 2010
2 Abstracts of Papers, Posters and Videos to be presented at the SOGC 68th Annual Clinical Meeting. Available at: http://www.sogc.org/cmes/acm2012/english/documents/2012JOGCabstractSup.pdf.Last accessed June 2012.
3 Novo Nordisk Canada Topline Report: Vaginal Health: Insights, Views and Attitudes. September 2010
4 Mayo Clinic: Vaginal Atrophy Definition. Available at: http://mayoclinic.com/health/vaginal-atrophy/DS00770. Last accessed March 2012.
5 The Big Ow- Symptoms. Available at: http://www.thebigow.ca/WhatIsTheBigOw/WhatItFeelsLike.aspx Last accessed February 2012
6 SOGC guidelines R. E. Nappi and M. Kokot-Kierepa: Vaginal Health: Insights, Views & Attitudes (VIVA) - results from an international survey.
7R. E. Nappi and M. Kokot-Kierepa: Vaginal Health: Insights, Views & Attitudes (VIVA) - results from an international survey.


SOURCE Novo Nordisk Canada Inc.



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES